2-氨基丙基-5(6)-羧基苯并咪唑 | 110356-08-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 2-氨基丙基-5(6)-羧基苯并咪唑
• 英文名称: 2-Aminopropyl-5(6)-carboxy-benzimidazole
• 英文别名: 2-(3-aminopropyl)-3H-benzimidazole-5-carboxylic acid
• CAS: 110356-08-6
• 化学式: C₁₁H₁₃N₃O₂
• 分子量: 219.24
• InChiKey: MOGGNXJLMQHAPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  96.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV
  申请人：Graffinity Pharmaceuticals GmbH

  公开号：EP2812346A1

  公开（公告）日：2014-12-17
• [EN] LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV<br/>[FR] LIGANDS POUR ANTICORPS ET PURIFICATION DE PROTÉINE DE FUSION À FRAGMENT CONSTANT PAR CHROMATOGRAPHIE D'AFFINITÉ IV
  申请人：GRAFFINITY PHARMACEUTICALS GMBH

  公开号：WO2013117707A1

  公开（公告）日：2013-08-15

  The present invention relates to the use, for affinity purification of an antibody or an fragment of an antibody, of a ligand-substituted matrix comprising a support material and at least one ligand covalently bonded to the support material, the ligand being represented by formula (I) L-(Sp)v-Ar1-Am-Ar2 wherein L is the linking point on the support material to which the ligand is attached; Sp is a spacer group; v is 0 or 1; Am is an amide group -NR1-C(O)-, and wherein either NR1 is attached to Ar1 and -C(O)- is attached to Ar2, or -C(O)- is attached to Ar1 and NR1 is attached to Ar2; and R1 is hydrogen or C1 to C4 alkyl, more preferably hydrogen or methyl; and most preferably hydrogen; Ar1 is a 5-, 6- or 7-membered mononuclear aromatic ring or partially saturated aromatic ring connected to Sp or L via a chemical bond and which is optionally furthermore (a) attached to a further 5- or 6-membered mononuclear aromatic ring via a chemical bond; or (b) fused to a mononuclear or binuclear aromatic ring as part of a multinuclear ring system wherein Ar1 is directly connected to Am via a chemical bond present on the said 5-, 6- or 7- membered aromatic ring constituting Ar1, or indirectly via a chemical bond which is either present at the further 5- or 6-membered aromatic ring attached to Ar1, or on the further 5- or 6- membered aromatic ring fused to Ar1; and wherein Ar1 is either not further substituted or attached to at least one substituent selected from C1 to C4 alkyl; C3 and C4 cycloalkyl; C2 to C4 alkenyl;; C2 to C4 alkynyl; a halogen; C1 to C4 haloalkyl;;; hydroxyl-substituted C1 to C4 alkyl; C1 to C4 alkoxy; hydroxyl-substituted C1 to C4 alkoxy; halogen-substituted C1 to C4 alkoxy; C1 to C4 alkylamino; C1 to C4 alkylthio; -NO2; =O; =S; =NH; -OH?; and combinations thereof; Ar2 is a 5- or 6-membered mononuclear aromatic ring which is unsubstituted, or via a chemical bond attached to at least one substituent selected from C1 to C6 alkyl; C3 to C6 cycloalkyl; C2 to C6 alkenyl; C5 and C6 cycloalkenyl; C2 to C6 alkynyl; a halogen; C1 to C6 haloalkyl; hydroxyl-substituted C1 to C6 alkyl; C1 to C6 alkoxy; hydroxyl-substituted C1 to C6 alkoxy; halogen-substituted C1 to C6 alkoxy; C1 to C6 alkylamino; C1 to C6 alkylthio; carbamoyl; methylenedioxy; ethylenedioxy; -OH; SH; a 5- or 6-membered mononuclear aromatic ring; and combinations thereof; and wherein Ar2 optionally, further to the substituents to which it may be attached via a chemical bond as cited above, is fused to a 5- or 6-membered mononuclear aromatic ring as part of a multinuclear ring system.